BMSN Bio-Matrix Scientific Group Inc. BMSN
The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials), followed by exit. The approach is a highly focused analysis of issued patents in regenerative medicine, identification and acquisition of undervalued assets that have demonstrated proof of concept, and forming companies around these assets.
Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 1-2 years grows technologies from laboratory to an asset ready for spin-off or sale to feed the pipeline of Big Pharma.
The focus of Regen BioPharma, Inc. is to developing translational medicine platforms for the rapid commercialization of stem cell therapies and to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the purpose of increased quality of life. Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these.
The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials), followed by exit. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 1-2 years grows technologies from laboratory to an asset ready for spin-off or sale.
Areas of interest to the Company include:
- Diabetes
- Chronic Obstructive Pulmonary Disease (COPD)
- Heart Related illness
- Circulatory issues
Regen BioPharma is a wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. (otcqb:BMSN) (pinksheets:BMSN), a biotechnology company focused on the development of regenerative medicine therapies and tools. The Company is specifically focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to lung, heart, circulatory system and other internal organs.
Bio Matrix Scientific Group & IceWEB Inc Trend Review: (OTCQB: BMSN), (OTCQB: IWEB)
Apr 05, 2013 (ACCESSWIRE-TNW via COMTEX) -- New York (April 5th, 2013) - Bio Matrix Scientific Group Inc. (OTCQB: BMSN) stock is at $0.0050, down 9.09 percent from its previous close of $0.01. The stock opened the session at $0.01 and it has traded 91.084 million shares so far. Bio Matrix Scientific Group's average daily volume stands at 65K shares. The company commands market capitalization of $5.99 million.
Bio Matrix Scientific Group develops regenerative medicine therapies. It also markets stem cell therapies. The company is based out of La Mesa in California and it was formed in 2005.
Find out if BMSN could bounce back in the upcoming trading sessions here:
http://stockreportdaily.com/market-scan/?symbol=BMSN
IceWEB Inc. (OTCQB: IWEB) opened at $0.05 and oscillated in the range of $0.04 and $0.05 in the latest trading session. It is at $0.04, down 12.11 percent from its previous close of $0.04. IceWEB shows bearish trend as it made the downward movement with higher than average volume of 5.123 million shares. Its regular volume stands at 2.243 million shares. The stock's first resistance level is at $0.045. Upon breaching this level, the stock may touch $0.05. On the downside, it may slip to $0.03.
The company announced its second significant sales of Unified storage solutions in Canada. IceWEB manufactures and markets cloud and network storage solutions.
Find out what the market could have in store for IWEB here:
http://stockreportdaily.com/market-scan/?symbol=IWEB
ABOUT US:
Stockreportdaily.com issues momentum alerts on stocks that can provide gains to day traders. Stockreportdaily.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. Stockreportdaily.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Stockreportdaily.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Stockreportdaily.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.Stockreportdaily.com
Disclosure: Stockreportdaily.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Stockreportdaily.com website, for complete risks and disclosures.
Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
For full disclaimer visit; http://www.Stockreportdaily.com/disclaimer/
Contact Info:
George Fitz
Stock Report Daily
info@Stockreportdaily.com
347-905-5009
